New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.Weight-loss drugs are expensive due to the high development costs and the limited time to recoup investment before patents expire.
Low-cost California-made Insulin Promised in 2024 Still Not AvailableCalifornia's low-cost insulin initiative faces significant delays and uncertainty, potentially leaving diabetics without affordable options for years.
Biden's parting gift to Big Pharma will hammer GLP-1 patients - like meThe Biden administration's decision to end the shortage of tirzepatide risks making this essential medication unaffordable for many Americans.
Trump Says The So-Called Fat Drug' Costs Too Much: It's Very Unfair'Trump highlights the stark price difference of diabetes medications between the U.S. and London, asserting unfairness in drug pricing practices.
Elon Musk and Bernie Sanders say they agree on one thing-cheaper OzempicThe U.S. healthcare system's failures unite unlikely political allies like Elon Musk and Bernie Sanders in the fight for affordable medication.
Pharmacy benefit management unicorn Capital Rx rakes in $3.5 billion in revenue as Congress targets drug middlemenCapital Rx reached $3.5 billion in revenue by avoiding profit from drug spending, focusing on transparency.
New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.Weight-loss drugs are expensive due to the high development costs and the limited time to recoup investment before patents expire.
Low-cost California-made Insulin Promised in 2024 Still Not AvailableCalifornia's low-cost insulin initiative faces significant delays and uncertainty, potentially leaving diabetics without affordable options for years.
Biden's parting gift to Big Pharma will hammer GLP-1 patients - like meThe Biden administration's decision to end the shortage of tirzepatide risks making this essential medication unaffordable for many Americans.
Trump Says The So-Called Fat Drug' Costs Too Much: It's Very Unfair'Trump highlights the stark price difference of diabetes medications between the U.S. and London, asserting unfairness in drug pricing practices.
Elon Musk and Bernie Sanders say they agree on one thing-cheaper OzempicThe U.S. healthcare system's failures unite unlikely political allies like Elon Musk and Bernie Sanders in the fight for affordable medication.
Pharmacy benefit management unicorn Capital Rx rakes in $3.5 billion in revenue as Congress targets drug middlemenCapital Rx reached $3.5 billion in revenue by avoiding profit from drug spending, focusing on transparency.
Medicare targets 15 more drugs for price negotiations including OzempicThe Biden administration has announced the next 15 drugs for Medicare price negotiation, including Ozempic, emphasizing affordable healthcare.
Medicare drug price negotiations: Here's a savings breakdownMedicare recipients will save $1.5 billion on medication costs starting in 2026 through negotiated drug prices.
Biden administration announces prices for 10 drugs in Medicare negotiations that will save $6 billionMedicare's new drug price negotiations will provide significant savings for older adults, impacting 10 commonly used and expensive medications.
Drugs to treat diabetes, heart disease and blood cancers among those affected by price negotiationsMedicare negotiation will save recipients $1.5 billion on medications starting in 2026.
Here's where Harris and Trump stand on three big health care issuesThe upcoming election could dramatically influence healthcare policy affecting millions of Americans.Two-thirds of Americans believe healthcare deserves more focus in the election discussions.
Medicare costs significantly lowered on popular prescription drugs for cancer, diabetes, heart disease and arthritisMedicare drug negotiations will significantly lower the cost of 10 high-cost drugs for enrollees, saving billions in coming years.
Medicare targets 15 more drugs for price negotiations including OzempicThe Biden administration has announced the next 15 drugs for Medicare price negotiation, including Ozempic, emphasizing affordable healthcare.
Medicare drug price negotiations: Here's a savings breakdownMedicare recipients will save $1.5 billion on medication costs starting in 2026 through negotiated drug prices.
Biden administration announces prices for 10 drugs in Medicare negotiations that will save $6 billionMedicare's new drug price negotiations will provide significant savings for older adults, impacting 10 commonly used and expensive medications.
Drugs to treat diabetes, heart disease and blood cancers among those affected by price negotiationsMedicare negotiation will save recipients $1.5 billion on medications starting in 2026.
Here's where Harris and Trump stand on three big health care issuesThe upcoming election could dramatically influence healthcare policy affecting millions of Americans.Two-thirds of Americans believe healthcare deserves more focus in the election discussions.
Medicare costs significantly lowered on popular prescription drugs for cancer, diabetes, heart disease and arthritisMedicare drug negotiations will significantly lower the cost of 10 high-cost drugs for enrollees, saving billions in coming years.
Other Barks and Bites for Friday, January 17: Teva Files IRA Challenge amid Second Round of Medicare Negotiations; Ninth Circuit Says Kinetic Sculptures Can Be Sufficiently 'Fixed' for Copyright; Second Circuit Affirms DMCA Safe Harbor Win for VimeoThe legal landscape around copyright and patents is evolving, driven by court decisions and regulatory actions.
FTC goes after drug middlemen for allegedly jacking up insulin pricesThe FTC is suing three PBMs for allegedly inflating insulin prices, impacting many Americans reliant on the drug.
Drug middlemen illegally drive up the cost of insulin, FTC saysFederal regulators accuse major pharmacy benefit managers of driving up insulin costs and limiting access to cheaper versions, impacting millions of diabetes patients.
Insurance Company Where CEO Was Assassinated Jacking Up Cost of Cancer Drugs by "Thousands of Percent," Government FindsOptumRx is accused of massively inflating the prices of life-saving medications, causing significant financial burdens for patients.
Bipartisan Lawmakers Seek to Break Up Giant Health Care ConglomeratesNew bipartisan legislation seeks to prevent health insurers from owning pharmacies, targeting the monopolistic power of pharmacy benefit managers.If enacted, this legislation could disrupt the current healthcare market dominated by a few conglomerates. The effort highlights ongoing concerns about drug pricing and transparency.
Healthcare Leaders Support FTC's Second Report on PBMs, While PBMs Criticize Findings - MedCity NewsFTC report reveals significant price hikes by PBMs on critical medications, calling for investigations into practices inflating drug costs and harming healthcare accessibility.
How a duty to spend wisely on worker benefits could loosen PBMs' grip on drug pricesA former J&J advocate is suing her employer over high drug costs due to its contract with a pharmacy benefit manager.The lawsuit shines light on the financial impacts of PBM relationships on employees.
FTC goes after drug middlemen for allegedly jacking up insulin pricesThe FTC is suing three PBMs for allegedly inflating insulin prices, impacting many Americans reliant on the drug.
Drug middlemen illegally drive up the cost of insulin, FTC saysFederal regulators accuse major pharmacy benefit managers of driving up insulin costs and limiting access to cheaper versions, impacting millions of diabetes patients.
Insurance Company Where CEO Was Assassinated Jacking Up Cost of Cancer Drugs by "Thousands of Percent," Government FindsOptumRx is accused of massively inflating the prices of life-saving medications, causing significant financial burdens for patients.
Bipartisan Lawmakers Seek to Break Up Giant Health Care ConglomeratesNew bipartisan legislation seeks to prevent health insurers from owning pharmacies, targeting the monopolistic power of pharmacy benefit managers.If enacted, this legislation could disrupt the current healthcare market dominated by a few conglomerates. The effort highlights ongoing concerns about drug pricing and transparency.
Healthcare Leaders Support FTC's Second Report on PBMs, While PBMs Criticize Findings - MedCity NewsFTC report reveals significant price hikes by PBMs on critical medications, calling for investigations into practices inflating drug costs and harming healthcare accessibility.
How a duty to spend wisely on worker benefits could loosen PBMs' grip on drug pricesA former J&J advocate is suing her employer over high drug costs due to its contract with a pharmacy benefit manager.The lawsuit shines light on the financial impacts of PBM relationships on employees.
Insulin Prices Dropped. But Some Poor Patients Are Paying More.Federal drug pricing policies can severely impact low-income individuals like Maricruz Salgado by raising their medication costs unexpectedly.
How a Company Makes Millions Off a Hospital Program Meant to Help the PoorThe expansion of a federal drug pricing program has led to increased healthcare costs, impacting patients and insurers significantly.Hospitals are profiting from a program intended for safety-net providers, raising concerns about ethical billing practices.
Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More - MedCity NewsMetabolic medicine dominated life sciences in 2024, driven by weight loss drugs and new market entrants.
PREVAIL Act Narrowly Moves Forward Despite Concerns About Drug Pricing ImpactThe PREVAIL Act is contentious, particularly regarding its potential impact on drug pricing and challenges to pharmaceutical patents.
'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearingThe U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.
Bernie Sanders grills Ozempic maker over high pricesNovo Nordisk CEO faced scrutiny in Congress over drug pricing and its moral implications for patients, especially in relation to high prices and access to medication.
Novo Nordisk sells hit weight-loss drug in China-at fraction of US priceWegovy's price in China is substantially lower than in the US, highlighting global disparities in drug pricing.
Ozempic producer CEO in hot seat in Senate hearing over cost of weight loss drugHigh prices for diabetes and obesity drugs like Ozempic are jeopardizing patient access, especially among low-income and minority groups.
'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearingThe U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.
Bernie Sanders grills Ozempic maker over high pricesNovo Nordisk CEO faced scrutiny in Congress over drug pricing and its moral implications for patients, especially in relation to high prices and access to medication.
Novo Nordisk sells hit weight-loss drug in China-at fraction of US priceWegovy's price in China is substantially lower than in the US, highlighting global disparities in drug pricing.
Ozempic producer CEO in hot seat in Senate hearing over cost of weight loss drugHigh prices for diabetes and obesity drugs like Ozempic are jeopardizing patient access, especially among low-income and minority groups.
Politicians' proposals would only minimally lower US drug prices, says reportMost popular drug pricing proposals may only slightly reduce costs; systemic change is needed.Single policy won't suffice—multiple strategies necessary to control drug prices.
Ozempic very likely' to see prices slashed in drug price negotiationsOzempic is likely to be included in upcoming drug price negotiations with the US government.
Ozempic 'very likely' to have price slashedOzempic is expected to be included in upcoming negotiations for price reductions under the US government's new drug pricing policies.
Politicians' proposals would only minimally lower US drug prices, says reportMost popular drug pricing proposals may only slightly reduce costs; systemic change is needed.Single policy won't suffice—multiple strategies necessary to control drug prices.
Ozempic very likely' to see prices slashed in drug price negotiationsOzempic is likely to be included in upcoming drug price negotiations with the US government.
Ozempic 'very likely' to have price slashedOzempic is expected to be included in upcoming negotiations for price reductions under the US government's new drug pricing policies.
How Health Care Affordability and Access Could Change under Harris or TrumpCandidates Harris and Trump plan to tackle U.S. health care issues but propose vastly different policies affecting drug costs and access to care.
How the Vice Presidential Candidates Compare on Health CareTim Walz's selection by Vice President Harris emphasizes health care as a crucial issue in the November presidential election.
How Health Care Affordability and Access Could Change under Harris or TrumpCandidates Harris and Trump plan to tackle U.S. health care issues but propose vastly different policies affecting drug costs and access to care.
How the Vice Presidential Candidates Compare on Health CareTim Walz's selection by Vice President Harris emphasizes health care as a crucial issue in the November presidential election.
Why the Proposed Rule on Terminal Disclaimers Should Not Be FinalizedThe USPTO should enhance examination practices for continuation applications while leaving policy decisions about patent thickets to Congress.
Chamber's GIPC Tells USPTO to Pivot on Coordination Plans with FDAActivists are urging the FDA to engage more in patent examination processes, but this initiative faces opposition from the U.S. Chamber of Commerce.
Why are the FDA and USPTO Ignoring Requests for Info on I-MAK?Senator Tillis questions FDA and USPTO on data supporting drug pricing proposals, emphasizes need for accurate information.
Why the Proposed Rule on Terminal Disclaimers Should Not Be FinalizedThe USPTO should enhance examination practices for continuation applications while leaving policy decisions about patent thickets to Congress.
Chamber's GIPC Tells USPTO to Pivot on Coordination Plans with FDAActivists are urging the FDA to engage more in patent examination processes, but this initiative faces opposition from the U.S. Chamber of Commerce.
Why are the FDA and USPTO Ignoring Requests for Info on I-MAK?Senator Tillis questions FDA and USPTO on data supporting drug pricing proposals, emphasizes need for accurate information.
Chamber, MSF Weigh in on Senate HELP Committee Hearing with Novo Nordisk CEOThe U.S. Chamber opposes price controls, claiming they hinder innovation and access to medications amid scrutiny of rising drug prices.
As Harris and Biden Take a Victory Lap on Drug Costs, She Sets the PaceBiden and Harris emphasize a united front while celebrating accomplishments like lowering drug costs, showcasing leadership and legacy.
HIV vaccine' could be made for just $40 a year for every patientLenacapavir, a new drug, could revolutionize HIV prevention if available affordably globally, priced at $40 a year instead of $42,250 currently.
C4IP Urges Senate Judiciary to Ignore Common Myths About Drug Patents'Evergreening' and 'patent thicketing' aren't a barrier to cheaper generics.
California joining with New Jersey company to make generic opioid overdose reversal drugCalifornia to sell generic Narcan to combat opioid overdose at a cheaper rate and aims to distribute it broadly.
Joe Biden and Bernie Sanders Demands Drug Companies Cut Price of Ozempic and Other New Weight Loss DrugsBiden and Sanders urge Novo Nordisk and Eli Lilly to lower prices of weight loss drugs for American patients.